ICD-10 Coding for Fibrocystic Breast Disease(N60.19, N60.19B, N60.19O)
Learn about ICD-10 coding for fibrocystic breast disease, including code N60.3 for fibrosclerosis with epithelial proliferation and N60.19 for benign changes.
Complete code families applicable to Fibrocystic Breast Disease
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| N60.3 | Fibrosclerosis of breast | Use when fibrosclerosis is confirmed via biopsy and imaging supports epithelial proliferation. |
|
| N60.19 | Other benign mammary dysplasia | Use for benign breast changes without epithelial proliferation. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutFibrocystic Breast Disease
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Fibrocystic Breast Disease.
Lack of laterality documentation
Impact
Clinical: Inaccurate treatment planning, Regulatory: Non-compliance with coding standards, Financial: Potential claim denials
Mitigation
Always document laterality in clinical notes, Use templates that prompt for laterality
Using N60.19 for cases with epithelial proliferation
Impact
Reimbursement: Incorrect coding may lead to claim denials., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Verify biopsy results and use N60.3 if epithelial proliferation is confirmed.
Biopsy Documentation
Impact
Lack of biopsy documentation for fibrosclerosis cases.
Mitigation
Implement mandatory biopsy documentation protocols.